---
title: "Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Safety questions"
description: "Safety questions on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the most common side effects of Gardasil 9? Does Gardasil 9 cause more injection-site reactions than Gardasil? How often did headache, fever, or nausea occur after Gardasil 9? How common were serious side effects with Gardasil 9 in clinical trials? 4 further questions follow. 8 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Safety questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Gardasil 9](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)

Safety questions that apply to every indication of Gardasil 9 are on [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications: Safety](https://www.evicenter.com/medical-information/gardasil-9/safety).

## Side effects

<a id="gardasil9-side-effects"></a>

### What are the most common side effects of Gardasil 9?

> “The most common (≥10%) local and systemic adverse reactions
> reported:
> • 
> In girls and women 16 through 26 years of age: injection-site pain
> (89.9%), injection-site swelling (40.0%), injection-site erythema
> (34.0%) and headache (14.6%). (6.1)
> • 
> In girls 9 through 15 years of age: injection-site pain (89.3%),
> injection-site swelling (47.8%), injection-site erythema (34.1%) and
> headache (11.4%). (6.1)
> • 
> In women 27 through 45 years of age: injection-site pain (82.8%),
> injection-site swelling (23.3%), injection-site erythema (16.9%),
> and headache (13.6%) (6.1)
> • 
> In boys and men 16 through 26 years of age: injection-site pain
> (63.4%), injection-site swelling (20.2%) and injection-site erythema
> (20.7%). (6.1)
> • 
> In boys 9 through 15 years of age: injection-site pain (71.5%),
> injection-site 
> swelling 
> (26.9%), 
> and 
> injection-site 
> erythema
> (24.9%). (6.1)”

Source: [GARDASIL 9: Prescribing information, page 1, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=1)

<a id="gardasil9-injection-site-vs-gardasil"></a>

### Does Gardasil 9 cause more injection-site reactions than Gardasil?

> “Injection-site reactions (pain, swelling, and erythema) and oral temperature were solicited using VRC-
> aided surveillance for five days after each injection of GARDASIL 9 during the clinical studies. The rates
> and severity of these solicited adverse reactions that occurred within five days following each dose of
> GARDASIL 9 compared with GARDASIL in Study 1 (girls and women 16 through 26 years of age) and
> Study 3 (girls 9 through 15 years of age) are presented in Table 1. Among subjects who received
> GARDASIL 9, the rates of injection-site pain were approximately equal across the three reporting time
> periods. Rates of injection-site swelling and injection-site erythema increased following each successive
> dose of GARDASIL 9. Recipients of GARDASIL 9 had numerically higher rates of injection-site reactions
> compared with recipients of GARDASIL.”

Source: [GARDASIL 9: Prescribing information, page 4, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=4)

<a id="gardasil9-headache-fever-nausea"></a>

### How often did headache, fever, or nausea occur after Gardasil 9?

> “Table 2: Rates (%) of Unsolicited Injection-Site and Systemic Adverse Reactions Occurring among ≥1.0% of Individuals
> after Any Vaccination with GARDASIL 9 Compared with GARDASIL (Studies 1 and 3)
>
> Girls and Women 16 through 26 Years of 
> Age
> Girls 9 through 15 Years of Age
>
> GARDASIL 9 
> N=7071 
> GARDASIL 
> N=7078 
> GARDASIL 9 
> N=299 
> GARDASIL
> N=300
> Injection-Site Adverse Reactions (1 to 5 Days Post-Vaccination, Any Dose)
> Pruritus 
> 5.5 
> 4.0 
> 4.0 
> 2.7
> Bruising 
> 1.9 
> 1.9 
> 0 
> 0
> Hematoma 
> 0.9 
> 0.6 
> 3.7 
> 4.7
> Mass 
> 1.3 
> 0.6 
> 0 
> 0
> Hemorrhage 
> 1.0 
> 0.7 
> 1.0 
> 2.0
> Induration 
> 0.8 
> 0.2 
> 2.0 
> 1.0
> Warmth 
> 0.8 
> 0.5 
> 0.7 
> 1.7
> Reaction 
> 0.6 
> 0.6 
> 0.3 
> 1.0
> Systemic Adverse Reactions (1 to 15 Days Post-Vaccination, Any Dose)
> Headache 
> 14.6 
> 13.7 
> 11.4 
> 11.3
> Pyrexia 
> 5.0 
> 4.3 
> 5.0 
> 2.7
> Nausea 
> 4.4 
> 3.7 
> 3.0 
> 3.7
> Dizziness 
> 3.0 
> 2.8 
> 0.7 
> 0.7
> Fatigue 
> 2.3 
> 2.1 
> 0 
> 2.7
> Diarrhea 
> 1.2 
> 1.0 
> 0.3 
> 0
> Oropharyngeal pain 
> 1.0 
> 0.6 
> 2.7 
> 0.7
> Myalgia 
> 1.0 
> 0.7 
> 0.7 
> 0.7
> Abdominal pain, upper 
> 0.7 
> 0.8 
> 1.7 
> 1.3
> Upper respiratory tract infection 
> 0.1 
> 0.1 
> 0.3 
> 1.0”

Source: [GARDASIL 9: Prescribing information, page 6, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=6)

> “The data for girls and women 16 through 26 years of age are from Study 1 (NCT00543543), and the data for girls 9 through 15
> years of age are from Study 3 (NCT01304498).”

Source: [GARDASIL 9: Prescribing information, page 6, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=6)

<a id="gardasil9-serious-adverse-events"></a>

### How common were serious side effects with Gardasil 9 in clinical trials?

> “Serious adverse events were collected throughout the entire study period (range one month to 48
> months post-last dose) for the seven clinical studies for GARDASIL 9. Out of the 15,705 individuals who
> were administered GARDASIL 9 and had safety follow-up, 354 reported a serious adverse event;
> representing 2.3% of the population. As a comparison, of the 7,378 individuals who were administered
> GARDASIL and had safety follow-up, 185 reported a serious adverse event; representing 2.5% of the
> population. Four GARDASIL 9 recipients each reported at least one serious adverse event that was
> determined to be vaccine-related. The vaccine-related serious adverse reactions were pyrexia, allergy to
> vaccine, asthmatic crisis, and headache.”

Source: [GARDASIL 9: Prescribing information, page 8, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=8)

<a id="gardasil9-gardasil-postmarketing"></a>

### Which postmarketing side effects were reported for Gardasil, the predecessor vaccine?

Applies to: GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

> “The postmarketing adverse experiences were reported voluntarily from a population of uncertain size,
> therefore, it is not possible to reliably estimate their frequency or to establish a causal relationship to
> vaccine exposure.”

Source: [GARDASIL 9: Prescribing information, page 9, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=9)

> “The safety profile of GARDASIL 9 and GARDASIL are similar. The postmarketing safety experience
> with GARDASIL is relevant to GARDASIL 9 since the vaccines are manufactured similarly and contain the
> same L1 HPV proteins of four of the same HPV types.”

Source: [GARDASIL 9: Prescribing information, page 9, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=9)

> “The following postmarketing adverse experiences have been spontaneously reported for GARDASIL:
> Blood and lymphatic system disorders: Autoimmune hemolytic anemia, idiopathic thrombocytopenic
> purpura, lymphadenopathy. 
> Respiratory, thoracic and mediastinal disorders: Pulmonary embolus.
> Gastrointestinal disorders: Nausea, pancreatitis, vomiting.
> General disorders and administration site conditions: Asthenia, chills, death, fatigue, injection-site
> nodule, malaise. 
> Immune 
> system 
> disorders: 
> Autoimmune 
> diseases, 
> hypersensitivity 
> reactions 
> including
> anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria.
> Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
> Nervous system disorders: Acute disseminated encephalomyelitis, dizziness, Guillain-Barré syndrome,
> headache, motor neuron disease, paralysis, seizures, syncope (including syncope associated with tonic-
> clonic movements and other seizure-like activity) sometimes resulting in falling with injury, transverse
> myelitis.
> Infections and infestations: Cellulitis.
> Vascular disorders: Deep venous thrombosis.”

Source: [GARDASIL 9: Prescribing information, page 10, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=10)

## Safety

<a id="gardasil9-deaths-in-trials"></a>

### Were any deaths linked to Gardasil 9 in clinical trials?

> “Across the clinical studies, ten deaths occurred (five each in the GARDASIL 9 and GARDASIL
> groups); none were assessed as vaccine-related. Causes of death in the GARDASIL 9 group included
> one automobile accident, one suicide, one case of acute lymphocytic leukemia, one case of hypovolemic
> septic shock, and one unexplained sudden death 678 days following the last dose of GARDASIL 9.
> Causes of death in the GARDASIL control group included one automobile accident, one airplane crash,
> one cerebral hemorrhage, one gunshot wound, and one stomach adenocarcinoma.”

Source: [GARDASIL 9: Prescribing information, page 8, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=8)

<a id="gardasil9-autoimmune-conditions"></a>

### How often were autoimmune conditions reported after Gardasil 9 in trials?

> “In all of the clinical trials with GARDASIL 9 subjects were evaluated for new medical conditions
> potentially indicative of a systemic autoimmune disorder. In total, 2.2% (351/15,703) of GARDASIL 9
> recipients and 3.3% (240/7,378) of GARDASIL recipients reported new medical conditions potentially
> indicative of systemic autoimmune disorders, which were similar to rates reported following GARDASIL,
> AAHS control, or saline placebo in historical clinical trials.”

Source: [GARDASIL 9: Prescribing information, page 8, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=8)

<a id="gardasil9-men-27-45-safety"></a>

### How was Gardasil 9 safety established in men 27 to 45?

Applies to: Men 27 through 45 years of age

> “Safety of GARDASIL 9 in men 27 through 45 years of age is inferred from the safety data of
> GARDASIL 9 in boys and men 9 through 26 years of age and girls and women 9 through 45 years of age
> and GARDASIL in individuals 9 through 45 years of age.”

Source: [GARDASIL 9: Prescribing information, page 4, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=4)

## Related pages
- [Medical information: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination)
- [Indication](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/guidelines)
